Where measurement research stands

Every trial depends on what it measures. Phase 3 trials in relapsing MS have mostly counted relapses, and those in progressive MS have counted disability worsening on the EDSS, a scale from 0 to 10 that depends heavily on walking.[1] Phase 2 trials usually count new lesions on MRI, because they respond to effective treatment within months.

These measures have limits. Disability often worsens without relapses: in a pooled analysis of the two large ocrelizumab trials in relapsing MS, most confirmed disability accumulation came from worsening independent of relapses.[2] The EDSS changes slowly and in coarse steps, so progression trials need hundreds of people followed for years.

Newer measures aim to show damage sooner. Blood neurofilament light, interpreted against healthy people of the same age, predicted later relapses and new lesions in a large Swiss cohort.[3] Paramagnetic rim lesions and slowly expanding lesions on MRI mark inflammation that persists inside the brain and go with faster worsening.[4][5] Optical coherence tomography and evoked potentials measure damage and repair along the visual pathway.

None of these yet replaces a clinical measure as the main proof that a medicine works for people with MS. The open question is which changes on a scan or in the blood reliably predict what matters to a person, such as walking, using the hands, thinking and fatigue.